Incorporating novel agents into frontline treatment of Hodgkin lymphoma
S Kambhampati, AF Herrera - Hematology, 2022 - ashpublications.org
Classical Hodgkin lymphoma (cHL) is associated with excellent outcomes with standard
frontline chemotherapy or combined modality therapy. However, up to 25% of patients will …
frontline chemotherapy or combined modality therapy. However, up to 25% of patients will …
SOHO State of the Art Updates and Next Questions| From Biology to Therapy: Progress in Hodgkin Lymphoma
KL Chohan, SM Ansell - Clinical Lymphoma Myeloma and Leukemia, 2023 - Elsevier
Classic Hodgkin lymphoma (HL) is a unique lymphoid malignancy where the malignant cells
comprise only 1% to 2% of the total tumor cellularity. Over the past 2 decades, the treatment …
comprise only 1% to 2% of the total tumor cellularity. Over the past 2 decades, the treatment …
[PDF][PDF] Highlights in Hodgkin Lymphoma From the 63rd American Society of Hematology Annual Meeting and Exposition
A Winter - hematologyandoncology.net
Brentuximab vedotin is an anti-body–drug conjugate that is directed at CD30 molecules
expressed by the Reed-Sternberg cell. This treatment induces immunogenic cell death. 1 …
expressed by the Reed-Sternberg cell. This treatment induces immunogenic cell death. 1 …